Idera to Present at Two Upcoming Investor Healthcare Conferences

CAMBRIDGE, Mass. and EXTON, Pa., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Vincent Milano, Idera's Chief Executive Officer will present a corporate update at the 2015 RBC Capital Markets' Global Healthcare Conference on Wednesday February 25, 2015 at 9:00 a.m. Eastern Time at the New York Palace Hotel.

Mr. Milano will also be presenting at the Cowen and Company 35th Annual Healthcare Conference on Monday, March 2, 2015 at 4:50 p.m. Eastern Time at the Boston Marriott Copley Place.

A live audio webcast of Idera's presentations will be accessible in the Investors and Media section of Idera's website at http://www.iderapharma.com. Archived versions will also be available on the Company's website after the event for 90 days.

About Idera Pharmaceuticals   

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and rare diseases. Idera's proprietary technology involves using a Toll-like receptor (TLR) targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA.

CONTACT: Investor and Media Contact
         Robert Doody
         Vice President, Investor Relations and
         Corporate Communications
         484-639-7235
         [email protected]

You May Also Be Interested In

• Open Society Launches $1.5 Million Earthquake Rebuilding Fund in Colombia
• XRP Price Prediction Targets $2 After Massive Rally but Wallets Buying Pepeto Know More
• Galantas Gold Reports Second Quarter 2026 Results